BR112019011070A2 - regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoide - Google Patents
regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoideInfo
- Publication number
- BR112019011070A2 BR112019011070A2 BR112019011070A BR112019011070A BR112019011070A2 BR 112019011070 A2 BR112019011070 A2 BR 112019011070A2 BR 112019011070 A BR112019011070 A BR 112019011070A BR 112019011070 A BR112019011070 A BR 112019011070A BR 112019011070 A2 BR112019011070 A2 BR 112019011070A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- drug
- fracture
- hormone receptor
- parathyroid hormone
- Prior art date
Links
- 102000006461 Parathyroid Hormone Receptors Human genes 0.000 title 1
- 108010058828 Parathyroid Hormone Receptors Proteins 0.000 title 1
- 230000010478 bone regeneration Effects 0.000 title 1
- 230000000638 stimulation Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 230000008685 targeting Effects 0.000 abstract 3
- 208000010392 Bone Fractures Diseases 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 101800000112 Acidic peptide Proteins 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 102100032256 Parathyroid hormone/parathyroid hormone-related peptide receptor Human genes 0.000 abstract 1
- 101710180613 Parathyroid hormone/parathyroid hormone-related peptide receptor Proteins 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 239000003263 anabolic agent Substances 0.000 abstract 1
- 230000001195 anabolic effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 abstract 1
- 229920000447 polyanionic polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0031—Rectum, anus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662428492P | 2016-11-30 | 2016-11-30 | |
| US201762553313P | 2017-09-01 | 2017-09-01 | |
| PCT/US2017/064081 WO2018102616A1 (en) | 2016-11-30 | 2017-11-30 | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019011070A2 true BR112019011070A2 (pt) | 2019-10-01 |
Family
ID=62241919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019011070A BR112019011070A2 (pt) | 2016-11-30 | 2017-11-30 | regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoide |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20200317745A1 (enExample) |
| EP (1) | EP3548012A4 (enExample) |
| JP (2) | JP7649624B2 (enExample) |
| CN (1) | CN110114065A (enExample) |
| AU (1) | AU2017367699B2 (enExample) |
| BR (1) | BR112019011070A2 (enExample) |
| CA (1) | CA3045458A1 (enExample) |
| IL (1) | IL266977B2 (enExample) |
| MX (1) | MX2019006189A (enExample) |
| WO (1) | WO2018102616A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3045458A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
| EP3796941A4 (en) * | 2018-05-30 | 2022-12-28 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| CN110551201B (zh) * | 2019-08-26 | 2020-04-28 | 杭州彗搏科技有限公司 | 一种新型骨形成蛋白2来源的环肽、制备方法及其应用 |
| CN114364327A (zh) * | 2019-09-12 | 2022-04-15 | 雷迪厄斯健康公司 | 用阿巴帕肽改善脊柱融合的方法 |
| CN112646042A (zh) * | 2019-10-10 | 2021-04-13 | 陕西麦科奥特科技有限公司 | 活性多肽化合物 |
| WO2022051555A2 (en) * | 2020-09-03 | 2022-03-10 | Rampart Bioscience, Inc. | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
| WO2022093373A1 (en) * | 2020-10-26 | 2022-05-05 | Purdue Research Foundation | Compounds,compositions and methods of use to treat bone fractures |
| JP2023547889A (ja) * | 2020-10-26 | 2023-11-14 | パーデュー・リサーチ・ファウンデーション | 脊椎融合を治療するための化合物、組成物、および使用の方法 |
| AU2022205801A1 (en) * | 2021-01-05 | 2023-07-13 | Radius Health, Inc. | Treatment of long bone fractures with abaloparatide |
| WO2023136866A1 (en) * | 2022-01-14 | 2023-07-20 | Novosteo Llc | Bone targeted treatment in osteogenesis imperfecta |
| WO2024246840A1 (en) * | 2023-06-01 | 2024-12-05 | Radius Health, Inc. | Methods for identification and quantitation of abaloparatide and related peptide impurities |
| WO2025019691A1 (en) * | 2023-07-19 | 2025-01-23 | Zymeron Corporation | Drug conjugates for bone marrow protection |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU9103791A (en) * | 1990-12-21 | 1992-07-22 | Allelix Biopharmaceuticals Inc. | Oxidation resistant variants of parathyroid hormone |
| WO1995002610A1 (en) * | 1993-07-13 | 1995-01-26 | Syntex (U.S.A.) Inc. | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis |
| EP1950224A3 (en) * | 1998-03-09 | 2008-12-17 | Zealand Pharma A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US7057012B1 (en) * | 1998-12-31 | 2006-06-06 | The General Hospital Corporation | PTH functional domain conjugate peptides, derivatives thereof and novel tethered ligand-receptor molecules |
| JP2000327583A (ja) | 1999-05-17 | 2000-11-28 | Medei Sci Puraningu:Kk | 骨指向性ホルモン誘導体 |
| WO2004062588A2 (en) * | 2003-01-06 | 2004-07-29 | University Of Utah | Water-soluble polymeric bone-targeting drug delivery system |
| HUE055861T2 (hu) | 2004-04-21 | 2021-12-28 | Alexion Pharma Inc | Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez |
| US7863238B2 (en) | 2004-06-10 | 2011-01-04 | Saint Louis University | Proteins with an attached short peptide of acidic amino acids |
| US20110046059A1 (en) * | 2005-09-06 | 2011-02-24 | Zelos Therapeutics, Inc. | Pharmaceutically acceptable formulations/compositions for peptidyl drugs |
| US7803770B2 (en) * | 2006-10-03 | 2010-09-28 | Radius Health, Inc. | Method of treating osteoporosis comprising administration of PTHrP analog |
| JP5375611B2 (ja) | 2006-10-03 | 2013-12-25 | ラジウス ヘルス，インコーポレイテッド | 骨同化作用を有するタンパク質のための薬物送達方法 |
| DK2155874T3 (en) * | 2007-04-09 | 2016-08-01 | Univ Arkansas | FUSION PROTEIN OF COLLAGE BINDING DOMAIN AND parathyroid hormone |
| PL2158319T4 (pl) * | 2007-05-11 | 2016-04-29 | Alexion Pharma Inc | Fosfataza alkaliczna kierowana do kości, zestawy i zastosowanie |
| WO2009141823A2 (en) * | 2008-05-22 | 2009-11-26 | Ramot At Tel Aviv University Ltd. | Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases |
| WO2012111852A1 (ja) * | 2011-02-17 | 2012-08-23 | 帝人ファーマ株式会社 | 椎体骨折治療剤及びその評価方法 |
| US20130006217A1 (en) * | 2011-04-22 | 2013-01-03 | Gary Hattersley | METHOD OF DRUG DELIVERY FOR PTH, PTHrP AND RELATED PEPTIDES |
| CN102824647B (zh) * | 2011-06-13 | 2014-07-23 | 香港中文大学 | 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法 |
| WO2014033540A2 (en) * | 2012-08-28 | 2014-03-06 | The Governors Of The University Of Alberta | Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods of making and using thereof |
| EP3016674A4 (en) | 2013-06-23 | 2017-03-15 | Wisconsin Alumni Research Foundation | Alpha-/beta-polypeptide analogs of parathyroid hormone (pth) and method of using same |
| EP4137147A3 (en) * | 2015-03-03 | 2023-04-05 | Radius Health, Inc. | Uses of abaloparatide in reducing fracture risk |
| WO2016196400A1 (en) * | 2015-05-29 | 2016-12-08 | Purdue Research Foundation | Bone fracture repair by targeting of agents that promote bone healing |
| CN106039316B (zh) * | 2016-05-03 | 2019-04-02 | 同济大学 | 一种基于多肽构建的成骨细胞靶向载体及其制备与应用 |
| CA3045458A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
| WO2022093373A1 (en) * | 2020-10-26 | 2022-05-05 | Purdue Research Foundation | Compounds,compositions and methods of use to treat bone fractures |
-
2017
- 2017-11-30 CA CA3045458A patent/CA3045458A1/en active Pending
- 2017-11-30 JP JP2019529240A patent/JP7649624B2/ja active Active
- 2017-11-30 MX MX2019006189A patent/MX2019006189A/es unknown
- 2017-11-30 BR BR112019011070A patent/BR112019011070A2/pt active Search and Examination
- 2017-11-30 CN CN201780073942.4A patent/CN110114065A/zh active Pending
- 2017-11-30 US US16/464,164 patent/US20200317745A1/en not_active Abandoned
- 2017-11-30 EP EP17875427.1A patent/EP3548012A4/en active Pending
- 2017-11-30 AU AU2017367699A patent/AU2017367699B2/en active Active
- 2017-11-30 IL IL266977A patent/IL266977B2/en unknown
- 2017-11-30 WO PCT/US2017/064081 patent/WO2018102616A1/en not_active Ceased
-
2020
- 2020-03-31 US US16/836,366 patent/US10960054B2/en active Active
-
2021
- 2021-02-24 US US17/184,400 patent/US20210283227A1/en active Pending
-
2022
- 2022-12-02 JP JP2022193738A patent/JP2023029957A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210283227A1 (en) | 2021-09-16 |
| CA3045458A1 (en) | 2018-06-07 |
| RU2019119701A (ru) | 2021-01-14 |
| AU2017367699A1 (en) | 2019-07-11 |
| AU2017367699B2 (en) | 2023-12-07 |
| JP2020500871A (ja) | 2020-01-16 |
| RU2019119701A3 (enExample) | 2021-02-16 |
| US20200316174A1 (en) | 2020-10-08 |
| EP3548012A4 (en) | 2020-07-22 |
| WO2018102616A1 (en) | 2018-06-07 |
| EP3548012A1 (en) | 2019-10-09 |
| JP2023029957A (ja) | 2023-03-07 |
| MX2019006189A (es) | 2019-11-18 |
| IL266977B1 (en) | 2023-09-01 |
| IL266977A (en) | 2019-07-31 |
| IL266977B2 (en) | 2024-01-01 |
| US10960054B2 (en) | 2021-03-30 |
| JP7649624B2 (ja) | 2025-03-21 |
| US20200317745A1 (en) | 2020-10-08 |
| CN110114065A (zh) | 2019-08-09 |
| AU2017367699A8 (en) | 2019-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019011070A2 (pt) | regeneração óssea direcionada à fratura através da estimulação do receptor de hormônio da paratireoide | |
| BR112019005351A2 (pt) | terapia combinada com agonistas de cnp de liberação controlada | |
| CL2019000266A1 (es) | Composición de cannabis. | |
| CL2018001007A1 (es) | Composiciones farmacéuticas para terapias combinadas (sol. divisional de n° 201702538). | |
| BR112014016672A8 (pt) | compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo | |
| MX2023009205A (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. | |
| MX2018000915A (es) | Dispositivo de control de dosificacion para dispositivos de suministro de farmacos inyectables. | |
| MX2017015599A (es) | Dispositivo de administracion de farmacos con resorte indicador audible. | |
| MX2015000990A (es) | Analogos del glucagon. | |
| BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
| BR112015026006A2 (pt) | métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor | |
| BR112015012739A2 (pt) | sistemas e métodos de guia ortopédico | |
| BR112016002646A2 (pt) | dispositivos e métodos de entrega de fármaco de múltiplas unidades | |
| AR105712A1 (es) | Composiciones de insulina de rápida acción | |
| BR112015006093A2 (pt) | combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington | |
| BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
| BR112014031372A2 (pt) | implantes/procedimentos relacionados ao avanço da tuberosidade tibial | |
| HK1255593A1 (zh) | 具有柱塞杆剂量控制机构的注射器 | |
| BR112021018456A2 (pt) | Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento | |
| BR112018013063A2 (pt) | combinação terapêutica inibidora de bromodomínio e proteína extra-terminal | |
| BR112017015285A2 (pt) | dispositivo de fixação transcraniano para pelo menos um cateter de drenagem | |
| CL2020000170A1 (es) | Composición para su uso en la prevención y el tratamiento de patologías del aparato cardiovascular. | |
| BR112015024464A2 (pt) | dispositivo de infusão com estrutura em camadas tendo componentes duráveis e descartáveis | |
| BR112017000312A2 (pt) | sistema de tratamento da saúde bucal para a aplicação de fosfato de cálcio amorfo, uso de um ou mais aminoácidos básicos, composição, e uso de um ou mais aminoácidos em um sistema de tratamento da saúde bucal | |
| BR112017014416A2 (pt) | sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |